Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.43 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | CA4 | P22748 | 3/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | TYMS | P04818 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4425287 | 0.78 | LMNA (0.46) | LMNACHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL6910822 | 0.77 | TYMS (0.41) | LMNATSHRALDH1A1TYMSCYP3A4 | |
| SCHEMBL11411519 | 0.76 | ALDH1A1 (0.44) | LMNAALDH1A1TYMSCYP3A4NFKB1 | |
| SCHEMBL4893786 | 0.75 | ALDH1A1 (0.46) | LMNACHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL3291846 | 0.75 | TYMS (0.39) | LMNATSHRALDH1A1TYMSCYP3A4 | |
| SCHEMBL2547540 | 0.74 | LMNA (0.57) | LMNACHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL11317946 | 0.74 | — | — | |
| Hydrochloric Acid SCHEMBL11789817 | 0.73 | ALDH1A1 (0.44) | LMNACHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL13577888 | 0.73 | CA4 (0.44) | LMNACHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL30525718 | 0.72 | LMNA (0.62) | LMNACHRM2CHRM4CHRM5CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 145 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970107-B1 | PHOTOSWITCHABLE HDAC INHIBITORS | MASSACHUSETTS GEN HOSPITAL (US) | 2023-11-15 | — | — | EP | claimed |
| US-12582644-B2 | O-GlcNAc transferase inhibitors and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2026-03-24 | — | — | US | disclosed |
| US-12377053-B2 | Cationic polymers | TRANSLATE BIO, INC. (US) | 2025-08-05 | — | — | US | disclosed |
| CN-120129676-A | Compounds, compositions, and methods thereof | 海湃泰克(北京)生物医药科技有限公司 | 2025-06-10 | — | — | CN | disclosed |
| US-20250171398-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | LANTHEUS MEDICAL IMAGING, INC. (US) | 2025-05-29 | — | — | US | disclosed |
| US-12312377-B2 | Biconjugatable labels and methods of use | Quantum-Si Incorporated (US) | 2025-05-27 | — | — | US | disclosed |
| CN-119930509-A | Cancer therapy targeting cancer stem cells | 治疗方案股份有限公司 | 2025-05-06 | — | — | CN | disclosed |
| CN-119775198-A | Cancer therapy targeting cancer stem cells | 治疗方案股份有限公司 | 2025-04-08 | — | — | CN | disclosed |
| CN-119452084-A | Oligonucleotide compositions and methods thereof | 波涛生命科学有限公司 | 2025-02-14 | — | — | CN | disclosed |
| CN-119403559-A | Lincomamides and uses thereof | 哈佛大学的校长及成员们 | 2025-02-07 | — | — | CN | disclosed |
| EP-2675278-A1 | METHODS FOR SYNTHESIZING MOLYBDOPTERIN PRECURSOR Z DERIVATIVES | Alexion Pharma International SARL (CH) | 2013-12-25 | — | — | EP | disclosed |
| US-20130144033-A1 | CATALYSTS AND METHODS FOR POLYMER SYNTHESIS | NOVOMER, INC. (US) | 2013-06-06 | — | — | US | disclosed |
| WO-2012112922-A1 | METHODS FOR SYNTHESIZING MOLYBDOPTERIN PRECURSOR Z DERIVATIVES | ALEXION PHARMACEUTICALS, INC. (US) | 2012-08-23 | — | — | WO | disclosed |
| CN-102369202-A | Azaquinolinone derivatives and uses thereof | LINK MEDICINE CORP | 2012-03-07 | — | — | CN | disclosed |
| CN-102365025-A | Conjugate-based systems for controlled drug delivery | SMARTCELLS INC | 2012-02-29 | — | — | CN | disclosed |
| US-20110144306-A1 | LIGATION OF STAPLED POLYPEPTIDES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2011-06-16 | — | — | US | disclosed |
| US-20100292292-A1 | Treatment of Neurodegenerative Diseases Using Indatraline Analogs | LINK MEDICINE CORPORATION (US) | 2010-11-18 | — | — | US | disclosed |
| US-6849760-B2 | Method of preparing retroviral protease inhibitor intermediates | G. D. SEARLE & CO. (US) | 2005-02-01 | — | — | US | disclosed |
| US-20030171612-A1 | Method of preparing retroviral protease inhibitor intermediates | G.D. SEARLE & CO. | 2003-09-11 | — | — | US | disclosed |
| EP-0181061-A1 | Labelling organic molecules with sulphur-35 | AMERSHAM INTERNATIONAL plc (GB) | 1986-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171398-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | FABP3, TNNI3, TNNT2 | LMNA 2328/4885CHRM2 3005/4885CHRM4 2714/4885 |
| US-12312377-B2 | Biconjugatable labels and methods of use | CLTB, HLCS, CD44 | LMNA 1007/4885CHRM2 4337/4885CHRM4 4066/4885 |
| US-12582644-B2 | O-GlcNAc transferase inhibitors and uses thereof | OGA, OGT, OSTC | LMNA 2649/4885CHRM2 2932/4885CHRM4 3926/4885 |
| US-20030171612-A1 | Method of preparing retroviral protease inhibitor intermediates | ACE, REN, MME | LMNA 3199/4885CHRM2 4644/4885CHRM4 4673/4885 |
| US-12377053-B2 | Cationic polymers | RNMT, POLRMT, PARG | LMNA 737/4885CHRM2 4680/4885CHRM4 4861/4885 |
| US-20130144033-A1 | CATALYSTS AND METHODS FOR POLYMER SYNTHESIS | PPOX, COASY, SOD1 | LMNA 3764/4885CHRM2 3307/4885CHRM4 1228/4885 |
| US-20100292292-A1 | Treatment of Neurodegenerative Diseases Using Indatraline Analogs | HTT, SNCA, PARK7 | LMNA 652/4885CHRM2 104/4885CHRM4 362/4885 |
| US-20110144306-A1 | LIGATION OF STAPLED POLYPEPTIDES | MYC, MYCBP, MYCBP2 | LMNA 3489/4885CHRM2 4875/4885CHRM4 4850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.